483
Baxter Oncology GmbHBaxter Oncology GmbH – FDA 483, Aug 27, 2024
Record Details
Baxter Oncology GmbH, a drug product manufacturer in Halle Westfalen, was cited for multiple significant deficiencies during an FDA inspection. Observations included failures in aseptic process simulation, uncalibrated manufacturing equipment, unclear drug substance storage, deficient validation, non-adherence to SOPs, and inadequate facility and equipment maintenance, all impacting drug product quality and sterility assurance.
View Company Profile
ID · 2af708b1-9a7e-4ae2-970f-cadc4ee74ce6
Other documents for Baxter Oncology GmbH
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.